Codexis Stock Today
| CDXS Stock | USD 4.59 0.03 0.66% |
Performance15 of 100
| Odds Of DistressLess than 9
|
Codexis is selling for under 4.59 as of the 28th of November 2024; that is 0.66 percent increase since the beginning of the trading day. The stock's lowest day price was 4.47. Codexis has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. Note, on May 8, 2018, Representative Lamar Smith of US Congress acquired under $15k worth of Codexis's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of April 2010 | Category Healthcare | Classification Health Care |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company was incorporated in 2002 and is headquartered in Redwood City, California. Codexis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 81.38 M outstanding shares of which 1.95 M shares are currently shorted by private and institutional investors with about 2.74 trading days to cover. More on Codexis
Moving together with Codexis Stock
Moving against Codexis Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Codexis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Stephen MBBS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Synthetics, Chemicals Makers, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCodexis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Codexis' financial leverage. It provides some insight into what part of Codexis' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Codexis (CDXS) is traded on NASDAQ Exchange in USA. It is located in 200 Penobscot Drive, Redwood City, CA, United States, 94063 and employs 174 people. Codexis is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 371.08 M. Codexis conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 81.38 M outstanding shares of which 1.95 M shares are currently shorted by private and institutional investors with about 2.74 trading days to cover.
Codexis currently holds about 90.11 M in cash with (52.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Check Codexis Probability Of Bankruptcy
Ownership AllocationCodexis holds a total of 81.38 Million outstanding shares. The majority of Codexis outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Codexis to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Codexis. Please pay attention to any change in the institutional holdings of Codexis as this could imply that something significant has changed or is about to change at the company. On May 8, 2018, Representative Lamar Smith of US Congress acquired under $15k worth of Codexis's common stock.
Check Codexis Ownership Details
Codexis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-06-30 | 1.5 M | |
| Kent Lake Capital Llc | 2024-06-30 | 1.3 M | |
| Federated Hermes Inc | 2024-09-30 | 1.3 M | |
| Assenagon Asset Management Sa | 2024-09-30 | 1.1 M | |
| Paradigm Capital Management, Inc. | 2024-06-30 | 900 K | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 895.7 K | |
| Abrdn Plc | 2024-09-30 | 800.4 K | |
| Two Sigma Advisers, Llc | 2024-06-30 | 632.5 K | |
| Northern Trust Corp | 2024-09-30 | 589.9 K | |
| Opaleye Management Inc | 2024-09-30 | 8.8 M | |
| Casdin Capital, Llc | 2024-09-30 | 8.1 M |
Codexis Historical Income Statement
Codexis Stock Against Markets
Codexis Corporate Management
| Sriram MBA | Chief Officer | Profile | |
| Georgia Erbez | Chief Officer | Profile | |
| MBA Taylor | VP CFO | Profile | |
| Asli Aras | VP Devel | Profile | |
| Margaret JD | General Officer | Profile | |
| John Schiffhauer | Senior Property | Profile |
Additional Tools for Codexis Stock Analysis
When running Codexis' price analysis, check to measure Codexis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Codexis is operating at the current time. Most of Codexis' value examination focuses on studying past and present price action to predict the probability of Codexis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Codexis' price. Additionally, you may evaluate how the addition of Codexis to your portfolios can decrease your overall portfolio volatility.